-C M Thompson Researcher Activity Profile

Research Author Detailed Information 

C M Thompson Publication Rate By Year

C M Thompson has published 1 paper(s) in 2001, 10 paper(s) in 2007, 3 paper(s) in 2008, for a total of 14 research publications in total.

C M Cm Thompson Author Information

LAST NAME: thompson

FIRST NAME: C M

INITIALS: cm

AFFILIATION:

Papers

C M Thompson's Publication Record

1. Regulation of both gene expression and protein stability provides genetically assisted target evaluation (GATE) for microbial target validation. Year Published: 2001
Anadys Pharmaceuticals, Inc., 9050 Camino Santa Fe, San Diego, CA 92121, USA.
2. Analysis of probe level patterns in Affymetrix microarray data. Year Published: 2007
Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences, University of Louisville, Louisville, Kentucky, USA. accamb01@louisville.edu <accamb01@louisville.edu>
3. Serum antipneumococcal antibodies and pneumococcal colonization in adults with chronic obstructive pulmonary disease. Year Published: 2007
Division of Infectious Diseases, Department of Medicine, Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. Richard.Malley@childrens.harvard.edu
4. Tetrapeptide inhibitors of the glutamate vesicular transporter (VGLUT). Year Published: 2007
Center for Structural and Functional Neuroscience, Department of Biomedical and Pharmaceutical Sciences, The University of Montana, Missoula, MT 59812, USA.
5. SpxB is a suicide gene of Streptococcus pneumoniae and confers a selective advantage in an in vivo competitive colonization model. Year Published: 2007
Department of Epidemiology and Department of Immunology and Infectious Diseases, Harvard School of Public Health, 677 Huntington Ave., Boston, MA 02115, USA. gregev@hsph.harvard.edu
6. Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Year Published: 2007
Division of Infectious Diseases, Children's Hospital Boston, Enders 861.3, 300 Longwood Avenue, Boston, MA 02115, USA.
7. Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine. Year Published: 2007
Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA. mlipsitc@hsph.harvard.edu
8. Mechanistic considerations for formaldehyde-induced bronchoconstriction involving s-nitrosoglutathione reductase. Year Published: 2007
National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Washington, DC, USA.
9. Mechanistic considerations for formaldehyde-induced bronchoconstriction involving S-nitrosoglutathione reductase. Year Published: 2007
National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Washington, DC, USA.
10. Tetrapeptide inhibitors of the glutamate vesicular transporter (VGLUT). Year Published: 2007
Center for Structural and Functional Neuroscience, Department of Biomedical and Pharmaceutical Sciences, The University of Montana, Missoula, MT 59812, USA.
11. Mechanistic considerations for formaldehyde-induced bronchoconstriction involving S-nitrosoglutathione reductase. Year Published: 2007
National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Washington, DC, USA.
12. Efficient digestion and mass spectral analysis of vesicular glutamate transporter 1: a recombinant membrane protein expressed in yeast. Year Published: 2008
charles.thompson@umontana.edu.
13. Purification and proteomic analysis of synaptic vesicles. Year Published: 2008
Department of Pharmaceutical Sciences, University of Montana, Missoula, MT.
14. Identification of glucose-dependant insulin secretion targets in pancreatic beta cells by combining defined-mechanism compound library screening and siRNA gene silencing. Year Published: 2008
Merck & Co Inc, Target Validation, Merck Research Laboratory, Rahway, NJ 07065, USA.